ISSN: 1859 - 2872
Survey on the use of remdesivir in inpatients with COVID-19 at Nguyen Tri Phuong Hospital
Main Article Content
Keywords
Abstract
Objective: To investigate the characteristics of drug use, results of treatment with remdesivir and influencing factors in COVID-19 inpatients prescribed with remdesivir. Subject and method: A descriptive and retrospective, cross-sectional study was based on COVID-19 inpatient medical records prescribed with remdesivir from August 1, 2021 to December 31, 2021. Result: In 92 patients receiving remdesivir, the severe COVID-19 cases on admission accounted for 39.1%, 61% required oxygen support, 90.2% had pulmonary infiltrates. The majority of patients were prescribed with antibiotics (96.6%), anticoagulant (97.8%), and anti-inflammatory (93.7%), concurrently with remdesivir. Dosage, route of administration and administration of remdersivir were completely consistent with guideline. There were 23.9% who were not in the indicated group and 4.3% were treated for less than 5 days with remdesivir due to death. There was a patient with elevated liver enzymes. The majority of patients had clinical improvement (83.7%) and had a discharge with favorable outcomes (89.1%) with a median hospital stay of 11.5 (4-41). The mortality rate accounted for 8.7%. The duration of the patient's respiratory support was the only factor affecting the hospital stay (p=0.013 and OR = 0.341 (0.145-0.798)). Conclusion: The majority of hospitalized patients with COVID-19 in the study improved clinically and achieved good results. However, randomized controlled studies are needed to evaluate the therapeutic effect of remdesivir on COVID-19 patients
Article Details
References
2. Bùi Thanh Huyền (2022) Hiệu quả của remdesivir trên bệnh nhân điều trị COVID - 19 tại Bệnh viện đa khoa Đồng Nai năm 2021. Tạp chí Y học thành phố Hồ Chí Minh tập 26 (1), tr. 292-298.
3. RECOVERY Collaborative Group (2022) Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. The Lancet 400(10349): 359-368.
4. Goverment of United Kingdom (2022) Guidance COVID-19: Epidemiology, virology and clinical features. UK Health Security Agency.
5. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD (2020) Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS central Science 6(5): 672-683.
6. Lee S, Santarelli A, Caine K, Schritter S, Dietrich T, Ashurst J (2022) Remdesivir for the treatment of severe COVID-19: a community hospital's experiencr. Journal of Osteopathic Medicine 120(12): 926-933.
7. Polivka L, Gajdacsi J, Fazekas L, Sebok S, Barczi E, Hidvegi E, Sutto Z, Dinya E, Maurovich-Horvat P, Szabo AJ, Merkely B, Müller V (2022) Long-term survival benefit of male and multimorbid COVID-19 patients with 5-day remdesivir treatment. Journal of Global Health.
8. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C (2022) Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. The Lancet 395(10236): 1569-1578. DOI: 10.1016/S0140-6736(20)31022-9.
Article Sidebar
